Neurodegenerative disease is a completely different application than anything previously discussed for Iclusig. As you pointed out the ability to penetrate the BB barrier is only one aspect of potential efficacy. So far the overwhelming majority of trials for efficacious drugs in these indications have been costly exercises in futility. I hope they are doing preclinical studies. Perhaps someone else is going to be doing studies using the drug.
Look at World Patent, page 88 in the description section (near the end). There is a chart showing blood and brain concentrations and this is where the 30mg dose is suggested.
News 
Market Data 
Discover 
